Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis

Neurooncol Adv. 2021 Jul 10;3(1):vdab095. doi: 10.1093/noajnl/vdab095. eCollection 2021 Jan-Dec.

Authors

Iyad Alnahhas¹, Mouaz Alsawas², Appaji Rayi³, Joshua D Palmer⁴, Raju Raval⁴, Shirley Ong³, Pierre Giglio³, Mohammad Hassan Murad², Vinay Puduvalli³

Affiliations

¹ Division of Neuro-Oncology, Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
² Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.
³ Division of Neuro-Oncology, Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
⁴ Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

Abstract

[This corrects the article DOI: 10.1093/noajnl/vdaa082.].

© The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

Publication types

Published Erratum